The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: The NOBORI PK study

Catheterization and Cardiovascular Interventions

Volumn 72, Issue 7, 2008, Pages 901-908

  Ostojic, Miodrag C ^a,g   Sagic, Dragan ^b   Jung, Robert ^b   Zhang, Yan Ling ^c   Nedeljkovic, Milan ^a   Mangovski, Ljupco J ^b   Stojkovic, Sinisa ^a   Debeljacki, Dragan ^b   Colic, Mirko ^b   Beleslin, Branko ^a   Milosavljevic, Brastislav ^b   Orlic, Dejan ^a   Topic, Dragan ^b   Karanovic, Nevena ^d   Paunovic, Dragica ^e   Christians, Uwe ^c,f   Antonic, Z ^b   Benz, D ^b   Ivanovic, V ^b   Bikicki, D ^b  

^a Clinical Center of Serbia   (Serbia)

^b Institute for Cardiovascular Disease   (Serbia)

^c UNIVERSITY OF COLORADO   (United States)

^d Ministry of Health   (Serbia)

^e Terumo Europe   (Belgium)

^f Eurofins Medinet Inc   (Germany)

^g UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Angioplasty; Biolimus A9; Coronary restenosis; Drug eluting stent; Pharmacokinetics

Indexed keywords

BIOLIMUS A9; RAPAMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELUTING STENT; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HUMAN; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CHROMATOGRAPHY, LIQUID; COLORADO; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; SERBIA; SIROLIMUS; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME;

EID: 60749131112     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21775     Document Type: Article

References (16)

1. Anis RR, Karsch KR, Oberhoff M. An update on clinical and pharmacological aspects of drug-eluting stents. Cardiovasc Hematol Disord Drug Targets 2006;6:245-255.
2. Slavin L, Chhabra A, Tobis JM. Drug-eluting stents: Preventing restenosis. Cardiol Rev 2007;15:1-12.
3. Morice MC, Serruys PW, Sousa JE, for the RAVEL study group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
4. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
5. Grube E, Buellesfeld L. BioMatrix Biolimus A9-eluting coronary stent: A next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices 2006;3:731-741.
6. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2003;2:222-232.
7. Kahan BD. Sirolimus: A comprehensive review. Expert Opin Pharmacother 2001;2:1903-1917.
8. Sehgal SN. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35:7S-14S.
9. Grube E, Hauptman KE, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of Biolimus A9 eluting stent with a bioerodable polymer coating. EuroInterv 2005;1:53-57.
10. Costa RA, Lansky AJ, Abizaid A, Mueller R, Tsuchiya Y, Mori K, Cristea E, Leon MB, Sousa JE, Schmidt T, Hauptmann KE, Grube E. Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol 2006;98:443-446.
11. Chevalier B, Serruys WP, Silber S, et al. Randomised comparison of Nobori, Biolimus A9-eluting coronary stent with a Taxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The Nobori 1 trial. EuroInterv 2007;2:426-434.
12. Ostojic M, Sagic D, Belesli B, et al., for the NOBORI CORE Clinical Investigators. First clinical comparison of Nobori-Biolimus A9 eluting stent with Cypher-sirolimus eluting stent; NOBORI CORE 9 months angiographic and one year clinical outcomes. EuroInterv 2008;3:574-579.
13. Hamilos M, Ostojic M, Beleslin B, Sagic D, Magovski Lj, Stojkovic S, Nedeljkovic M, Orlic D, Milosavljevic B, Topic D, Karanovic N, Wijns W. Differential effects of drug eluting stents on local endothelium dependent coronary vasomotion. J Am Coll Cardiol 2008;51:2123-2129.
14. Christians U, Jacobsen W, Serkova N, Benet LZ, Vidal C, Sewing KF, Manns MP, Kirchner GI. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: Immunosuppressants. J Chromatogr B 2000;748:41-53.
15. Zhang YL, Bendrick-Peart J, Strom T, Haschke M, Christians U. Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples. Ther Drug Monit 2005; 27:770-778.
16. Vetrovec GW, Rizik D, Williard C, Snead D, Piotrovski V, Kopia G. Sirolimus PK trial: A pharmacokinetic study of the sirolimus-eluting Bx Velocity stent in patients with de novo coronary lesions. Catheter Cardiovasc Interv 2006;67:32-37.